Healios KK (JP:4593) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Healios K.K. has reached a key milestone in their joint research with AND medical, securing a 60 million yen payment as part of an ongoing agreement focused on producing culture supernatant using Healios’ technology. The company anticipates beginning monthly supply of 25 liters of culture supernatant to AND medical in fiscal year 2025, with the possibility of increasing production based on demand. This collaboration aims to advance regenerative medicine, with Healios providing its expertise in stem cell technology for new therapy development.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue